Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy.
暂无分享,去创建一个
[1] S. Berkelhamer,et al. An update on the diagnosis and management of bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension. , 2018, Seminars in perinatology.
[2] A. Torbicki,et al. Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics. , 2018, International journal of cardiology.
[3] A. Bos,et al. Identification of gaps in the current knowledge on pulmonary hypertension in extremely preterm infants: A systematic review and meta‐analysis , 2018, Paediatric and perinatal epidemiology.
[4] H. Gall,et al. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH , 2018, Lung.
[5] A. Torbicki,et al. Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension , 2016, Heart.
[6] P. McNamara,et al. Hemodynamic instability in the critically ill neonate: An approach to cardiovascular support based on disease pathophysiology. , 2016, Seminars in perinatology.
[7] A. Sehgal,et al. Sildenafil therapy in bronchopulmonary dysplasia-associated pulmonary hypertension: a retrospective study of efficacy and safety , 2015, European Journal of Pediatrics.
[8] B. Hanna,et al. Safety of Epoprostenol and Treprostinil in Children Less than 12 Months of Age , 2013, Pulmonary circulation.
[9] Jan Marek,et al. Targeted Neonatal Echocardiography in the Neonatal Intensive Care Unit: practice guidelines and recommendations for training. Writing Group of the American Society of Echocardiography (ASE) in collaboration with the European Association of Echocardiography (EAE) and the Association for European Pedi , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[10] D. McElhinney,et al. Pulmonary Artery Hypertension in Formerly Premature Infants With Bronchopulmonary Dysplasia: Clinical Features and Outcomes in the Surfactant Era , 2007, Pediatrics.
[11] O. V. Evgenov,et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.
[12] Kazuki Nakamura,et al. Disturbances in nitric oxide/cyclic guanosine monophosphate system in SHR/NDmcr-cp rats, a model of metabolic syndrome. , 2006, Life sciences.
[13] W. Seeger,et al. Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling , 2006, Circulation.
[14] J. Wharton,et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. , 2005, American journal of respiratory and critical care medicine.
[15] K. Stenmark,et al. Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis , 2004, The Pediatric infectious disease journal.
[16] D. Harrison,et al. Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. , 2003, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[17] J. Stasch,et al. Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart Failure , 2003, Circulation.
[18] W. Seeger,et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.
[19] A. Bush,et al. Changes in pulmonary circulation in severe bronchopulmonary dysplasia. , 1990, Archives of disease in childhood.
[20] J. Fouron,et al. Value of echocardiography in assessing the outcome of bronchopulmonary dysplasia of the newborn. , 1980, Pediatrics.
[21] J. Stasch,et al. NO-independent, haem-dependent soluble guanylate cyclase stimulators. , 2009, Handbook of experimental pharmacology.